Skip to content

Clinical trials on safety of lobectomy by Da Vinci surgery system for resectable lung cancer.

Clinical trials on safety of lobectomy by Da Vinci surgery system for resectable lung cancer. - Lobectomy by Da Vinci surgery system for resectable lung cancer.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027438
Enrollment
10
Registered
2017-05-22
Start date
2017-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resectable lung cancer.

Interventions

Robot assisted lobectomy with da Vinci surgery system.

Sponsors

Hamamatsu University School of Medicine.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Clinical stage I lung cancer which can be completely resected by lobectomy surgery (with or without preoperative pathology diagnosis). 2) It is 20 years old to 80 years old. 3) PS (ECOG) is 0 or 1. 4) There is no history of thoracotomy or high degree of adhesion is not expected in the thoracic cavity. 5) It satisfies all the conditions below. (The latest inspection value within 28 days from the registration date is used for all inspection items.) - White blood cell count is 3,000 / mm3 or more. - Platelet count is 100,000 / mm3 or more. - AST is 100 IU / L or less / ALT is 100 IU / L or less. - Total bilirubin is 2.0 g / dl or less. - Serum creatinine is 1.5 mg / dl or more. 6) For patient participation, written consent has been obtained from the patient himself.

Exclusion criteria

Exclusion criteria: 1) Possible pregnancy or lactating women. 2) Psychosis or psychiatric symptoms are merged, and it is judged that participation in the examination is difficult. 3) Continuous systemic administration (ingestion or intravenous) of steroid drugs. 4) I have a history of myocardial infarction within 6 months or unstable angina. 5) Hypertension with poor control is complicated. 6) Diabetes mellitus with poor control. 7) Combined respiratory diseases requiring sustained oxygen therapy. 8) Other cases that the doctor in charge judged inappropriate.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative adverse events

Countries

Japan

Contacts

Public ContactAkikazu Kawase

Hamamatsu University School of Medicine. First department of surgery.

akawase@hama-med.ac.jp053-435-2276

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026